(S)-2-(benzyloxycarbonylamino)-1-((1S,2S,5S)-3,6-dioxabicycIo[3.1.0]hexan-2-yl)ethyl methanesulfonate | 1001660-38-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-(benzyloxycarbonylamino)-1-((1S,2S,5S)-3,6-dioxabicycIo[3.1.0]hexan-2-yl)ethyl methanesulfonate
• 英文别名: (S)-2-(benzyloxycarbonylamino)-1-((1S, 2S, 5S)-3,6-dioxabicyclo[3.1.0]hexan-2-yl)ethyl methanesulfonate；(S)-2-(Benzyloxycarbonylamino)-1-((1S,2S,5S)-3,6-dioxabicyclo[3.1.0]hexan-2-yl)ethyl methanesulfonate；[(1S)-1-[(1S,2S,5S)-3,6-dioxabicyclo[3.1.0]hexan-2-yl]-2-(phenylmethoxycarbonylamino)ethyl] methanesulfonate
• CAS: 1001660-38-3
• 化学式: C₁₅H₁₉NO₇S
• 分子量: 357.384
• InChiKey: OJGZBYPNIHMTOB-FQUUOJAGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (S)-2-(benzyloxycarbonylamino)-1-((1S,2S,5S)-3,6-dioxabicycIo[3.1.0]hexan-2-yl)ethyl methanesulfonate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 (3R,3aR,6S,6aS)-3-hydroxyhexahydro-2H-furo[3,2-b]pyrrol-6-yl methanesulfonate
  参考文献：
  名称：

  WO2008/7107

  摘要：

  公开号：
• 作为产物：
  描述：

  (S)-2-(benzyloxycarbonylamino)-1-((S)-2,5-dihydrofuran-2-yl)ethyl methane sulfonate 在 Oxone 、 1,1,1-三氟丙酮 、 碳酸氢钠 作用下， 以 水 、 乙腈 为溶剂， 反应 1.83h， 以59%的产率得到(S)-2-(benzyloxycarbonylamino)-1-((1S,2S,5S)-3,6-dioxabicycIo[3.1.0]hexan-2-yl)ethyl methanesulfonate
  参考文献：
  名称：

  WO2008/7107

  摘要：

  公开号：

文献信息

• Tetrahydrofuro[3,2-B] pyrrol-3-ones as cathepsin K inhibitors
  申请人：Amura Therapeutics Limited

  公开号：US07803803B2

  公开（公告）日：2010-09-28

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; one of R1 and R2 is H, and the other is selected from OR6, SR6, NR6R7, N3, Me, Et, CF3, SOR8 and SO2R8; R3 is selected from tert-butylmethyl, iso-propylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R4 is optionally substituted C1-8 alkyl or optionally substituted C3-8 cycloalkyl; R6 and R7 are each independently selected from H, C1-8-alkyl and C3-8-cycloalkyl, or R6 and R7 are linked to form a cyclic group together with the nitrogen to which they are attached; and R8 is C1-8-alkyl or C3-8-cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及公式(I)的化合物及其药学上可接受的盐，其中：X为CH或N；R1和R2中的一个为H，另一个选择自OR6、SR6、NR6R7、N3、Me、Et、CF3、SOR8和SO2R8；R3选择自叔丁基甲基、异丙基甲基、仲丁基、叔丁基、环戊基和环己基；R4为可选择性取代的C1-8烷基或可选择性取代的C3-8环烷基；R6和R7各自独立地选择自H、C1-8烷基和C3-8环烷基，或R6和R7与它们所附着的氮一起形成一个环状基团；R8为C1-8烷基或C3-8环烷基。本发明还涉及包含公式(I)化合物的药物组合物，以及在治疗骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛中使用这种化合物的用途。
• Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
  申请人：Quibell Martin

  公开号：US20090192322A1

  公开（公告）日：2009-07-30

  The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R 48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R 48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).

  本发明涉及一种制备式(Ia)、(Ib)、(Ic)或(Id)化合物或其药学上可接受的盐、水合物、溶剂合物、复合物或前药的方法，该方法包括以下步骤：(A) (i)用氧化剂处理式(IVa)化合物，其中R48是烷基或甲苯磺酰基，以形成式(Va)化合物；(ii)将所述式(Va)化合物转化为式(Ia)或(Ic)化合物；或(B) (i)用氧化剂处理式(IVb)化合物，其中R48是烷基或甲苯磺酰基，以形成式(Vb)化合物；(ii)将所述式(Vb)化合物转化为式(Ib)或(Id)化合物。
• Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases
  申请人：Quibell Martin

  公开号：US20090186831A1

  公开（公告）日：2009-07-23

  A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R 1 and R 2 is H, and the other is selected from OR 6 , SR 6 , NR 6 R 7 , N 3 , Me, Et, CF 3 , SOR 8 and SO 2 R 8 ; or R 1 and R 2 are both H; one of R 3 and R 4 is H, and the other is selected from tert-butylmethyl, iso-propylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; or R 3 and R 4 are joined together with the adjacent backbone carbon atom to form a spiro-C 5 -C 6 cycloalkyl group; R 6 and R 7 are each independently selected from H, C 1-8 -alkyl and C 3-8 -cycloalkyl; or R 6 and R 7 are linked to form a cyclic group together with the nitrogen to which they are attached; R 8 is C 1-8 -alkyl or C 3-8 -cycloalkyl; R 9 is a para-substituted 6-membered monocyclic aryl or heteroaryl ring which includes up to five heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  化合物的公式（I），或其药学上可接受的盐、水合物、复合物或前药，其中： - R1和R2中的一个是H，另一个被选择自OR6、SR6、NR6R7、N3、Me、Et、CF3、SOR8和SO2R8之中； - 或者R1和R2都是H； - R3和R4中的一个是H，另一个被选择自叔丁基甲基、异丙基甲基、仲丁基、叔丁基、环戊基和环己基之中； - 或者R3和R4与相邻的骨架碳原子结合形成螺环C5-C6环烷基； - R6和R7分别独立地被选择自H、C1-8烷基和C3-8环烷基； - 或者R6和R7与它们所连接的氮一起形成一个环状基团； - R8是C1-8烷基或C3-8环烷基； - R9是一个包含最多五个杂原子的对位取代的6元单环芳基或杂环芳基环。 该发明还涉及包括公式（I）的化合物的制药组合物，以及在治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛中使用这种化合物的用途。
• Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors
  申请人：Quibell Martin

  公开号：US20090197817A1

  公开（公告）日：2009-08-06

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; one of R 1 and R 2 is H, and the other is selected from OR 6 , SR 6 , NR 6 R 7 , N 3 , Me, Et, CF 3 , SOR 8 and SO 2 R 8 ; R 3 is selected from tert-butylmethyl, iso-propylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R 4 is optionally substituted C 1-8 alkyl or optionally substituted C 3-8 cycloalkyl; R 6 and R 7 are each independently selected from H, C 1-8 -alkyl and C 3-8 -cycloalkyl, or R 6 and R 7 are linked to form a cyclic group together with the nitrogen to which they are attached; and R 8 is C 1-8 -alkyl or C 3-8 -cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中：X为CH或N；R1和R2中的一个为H，另一个选自OR6、SR6、NR6R7、N3、Me、Et、CF3、SOR8和SO2R8；R3选自叔丁基甲基、异丙基甲基、仲丁基、叔丁基、环戊基和环己基；R4为可选取代的C1-8烷基或可选取代的C3-8环烷基；R6和R7各自独立选自H、C1-8烷基和C3-8环烷基，或者R6和R7与它们所连接的氮一起形成一个环状基团；R8为C1-8烷基或C3-8环烷基。本发明还涉及包含式（I）化合物的药物组合物，以及在治疗骨质疏松症、帕盖特病、恰加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛方面使用这种化合物的方法。
• WO2008/7132
  申请人：——

  公开号：——

  公开（公告）日：——